FDA Tweaks Biosimilar Application Review Program

September 25, 2021

Biosimilar User Fee Act reviews have been slowed by the pandemic and the FDA has opened a public comment period as it plots the course through 2027.

Cardinal Health Biosimilars Expert Discusses Dynamics of Byooviz Launch
The Top 5 Biosimilar Articles for the Week of September 20
AAO Reacts to Ranibizumab Biosimilar Approval
Amgen Estimates $9.8 Billion in Cumulative US Biosimilar Savings